Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) Sees Significant Increase in Short Interest

Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) saw a large growth in short interest in January. As of January 30th, there was short interest totaling 1,615 shares, a growth of 382.1% from the January 15th total of 335 shares. Approximately 0.0% of the company’s stock are short sold. Based on an average trading volume of 19,331 shares, the days-to-cover ratio is currently 0.1 days. Based on an average trading volume of 19,331 shares, the days-to-cover ratio is currently 0.1 days. Approximately 0.0% of the company’s stock are short sold.

Alterity Therapeutics Price Performance

NASDAQ ATHE opened at $3.48 on Wednesday. Alterity Therapeutics has a 12 month low of $2.52 and a 12 month high of $7.00. The stock has a 50 day moving average of $3.27 and a 200-day moving average of $4.07.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Citadel Advisors LLC bought a new stake in shares of Alterity Therapeutics in the 3rd quarter valued at about $83,000. HB Wealth Management LLC bought a new position in Alterity Therapeutics during the third quarter worth about $220,000. Greenleaf Trust increased its position in Alterity Therapeutics by 88.2% during the third quarter. Greenleaf Trust now owns 32,000 shares of the company’s stock worth $120,000 after buying an additional 15,000 shares during the last quarter. Finally, Twin Lakes Capital Management LLC increased its position in Alterity Therapeutics by 2,250.3% during the third quarter. Twin Lakes Capital Management LLC now owns 139,258 shares of the company’s stock worth $524,000 after buying an additional 133,333 shares during the last quarter. Institutional investors own 2.14% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently commented on ATHE shares. Canaccord Genuity Group started coverage on shares of Alterity Therapeutics in a research report on Wednesday, December 17th. They issued a “speculative buy” rating on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Alterity Therapeutics in a research note on Wednesday, January 21st. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold”.

About Alterity Therapeutics

Alterity Therapeutics is a clinical-stage biotechnology company focused on the development of novel treatments for neurological and neurodegenerative disorders. The company’s research portfolio centers on small molecules designed to target underlying disease mechanisms, with an emphasis on improving synaptic function and mitigating neuroinflammation.

Among its lead assets is trofinetide (NNZ-2566), a peptide analog derived from insulin-like growth factor 1, which is being investigated for the treatment of Rett syndrome and Fragile X syndrome in ongoing clinical trials.